Compare WATT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | TNYA |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 171.4M |
| IPO Year | 2014 | 2021 |
| Metric | WATT | TNYA |
|---|---|---|
| Price | $23.88 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 273.4K | ★ 3.5M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,154,009.00 | N/A |
| Revenue This Year | $179.91 | N/A |
| Revenue Next Year | $126.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.53 |
| 52 Week High | $36.98 | $2.35 |
| Indicator | WATT | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 42.50 |
| Support Level | $21.41 | $0.65 |
| Resistance Level | $32.00 | $0.82 |
| Average True Range (ATR) | 2.51 | 0.06 |
| MACD | -0.69 | -0.01 |
| Stochastic Oscillator | 12.53 | 15.95 |
Energous Corp has developed scalable, over-the-air Wireless Power Network (WPN) technology that integrates semiconductor chipsets, software controls, hardware designs, and antenna systems to enable radio frequency (RF)-based charging for ambient Internet of Things (ambient IoT) devices, transforming supply chain capabilities from limited tracking to overall business intelligence. The WPN technology consists of transmitter systems, receiver integrated circuits, and supporting software designed to deliver power and data to battery-free IoT devices across a range of operating distances and power levels. Its applications include retail sensors, electronic shelf labels (ESLs), asset trackers, air quality monitors, motion detectors, and other monitoring solutions.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.